A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy

Japanese Journal of Clinical Oncology

Volumn 39, Issue 11, 2009, Pages 745-750

  Miwa, Sotaro ^a   Mizokami, Atsushi ^a   Konaka, Hiroyuki ^a   Izumi, Kouji ^a   Nohara, Takahiro ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Bone metastasis; Lung metastasis; Pleural metastasis; Renal cell carcinoma; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHA INTERFERON; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; IMUNACE; INTERLEUKIN 2; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG LOBECTOMY; LUNG METASTASIS; MONOTHERAPY; NEPHRECTOMY; PLEURA EFFUSION; PLEURA METASTASIS; THORACOCENTESIS;

ADULT; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; PLEURAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70449386887     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp122     Document Type: Article

References (12)

1. Saito H. Distant metastasis from renal adenocarcinoma. Cancer 1981;48:1487-91.
2. Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 1994;57:339-44.
3. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145-53.
4. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005;96:964-9.
5. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K, Namiki M. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 2003;169:281-2.
6. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002;38:91-102. Review.
7. Pandha H, Birchall L, Meyer B, Wilson N, Relph K, Anderson C, et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 2006;176:2255-61.
8. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The Bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65:8818-25.
9. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, et al. Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840-9.
10. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13:4482-6.
11. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004;114:623-33.
12. Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, et al. Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: Doubts no more. Expert Opin Biol Ther 2008;8:875-83.